Pharmacogenomics and pharmacogenetics: In silico prediction of drug effects in treatments for novel coronavirus SARS-CoV2 disease

Concetta Cafiero, Agnese Re, Alessandra Micera, Raffaele Palmirotta, Delio Monaco, Francesca Romano, Claudia Fabrizio, Raffaele Di Francia, Andrea Cacciamani, Pier Luigi Surico, Gerardo D’amato, Salvatore Pisconti

Research output: Contribution to journalArticlepeer-review


The latest developments in precision medicine allow the modulation of therapeutic approaches in different pathologies on the basis of the specific molecular character-ization of the patient. This review of the literature coupled with in silico analysis was to provide a selected screening of interactions between single-nucleotide polymorphisms (SNPs) and drugs (repurposed, investigational, and biological agents) showing efficacy and toxicityin counteracting Covid-19 infection. In silico analysis of genetic variants related to each drug was performed on such databases as PharmGKB, Ensembl Genome Browser,, and SNPedia, with an extensive literature review of papers (to May 10, 2020) on Covid-19 treatments using Medline, Embase, International Pharmaceutical Abstracts, PharmGKB, and Google Scholar. The clinical relevance of SNPs, known as both drug targets and markers, considering genetic variations with known drug responses, and the therapeutic consequences are discussed. In the context of clinical treatment of Covid-19, including infection prevention, control measures, and supportive care, this review high-lights the importance of a personalized approach in the final selection of therapy, which is probably essential in the management of the Covid-19 pandemic.

Original languageEnglish
Pages (from-to)463-484
Number of pages22
JournalPharmacogenomics and Personalized Medicine
Publication statusPublished - 2020


  • ADR
  • Covid-19
  • Drug effects
  • In silico
  • Pharmacogenetics
  • Pharmacogenomics
  • SARS-CoV2

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Pharmacogenomics and pharmacogenetics: In silico prediction of drug effects in treatments for novel coronavirus SARS-CoV2 disease'. Together they form a unique fingerprint.

Cite this